New Alzheimer’s Drug Gets FDA Approval

This week the Food and Drug Administration fully approved the first-ever Alzheimer’s treatment. Called Leqembi, the drug has been clinically proven to effectively slow the early progression of Alzheimer’s disease.

“Amyloid is a protein that aggregates between brain cells and neurons and causes death of those neurons,” said Dr. Michal Schnaider Beeri, director of the Alzheimer’s and Dementia Research Center at Rutgers Brain Health Institute. “Leqembi clears the amyloid, so the decline of the patient with Alzheimer’s is slower.”

Watch the Interview Michal Schnaider Beeri